Doctor of Osteopathy Program year 2024 Reported 2019–2024 Source: CMS Open Payments, 2026 publication

Tiffany Spaulding

Family Medicine Casper, WY Doctor of Osteopathy

NPI 1679704753 CMS profile 166644

1522 E A St, Casper, WY 82601

Open in the dashboard

General payments

$2,466

151 records reported · program years 2019–2024

Research payments

$0

Paid to them · None reported · program years 2019–2024

Ownership & investment interest

$0

None reported

Through program year 2024, Tiffany Spaulding of Casper, WY is reported in the CMS Open Payments database as having received $2,466 across 151 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 82nd percentile of Family Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $127 5
2023 General $367 21
2022 General $502 29
2021 General $563 37
2020 General $380 24
2019 General $528 35

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Tiffany Spaulding
  • Family Medicine median
  • Middle half of Family Medicine
  • National median

In program year 2025, general payments to Tiffany Spaulding were reported at $0. Among 56,786 Family Medicine profiles paid that year, the median was $155 and the middle half received between $45 and $549.

Show as a table
Year Tiffany Spaulding Family Medicine median Middle half National median
2019 $528 $150 $41–$543 $163
2020 $380 $120 $32–$415 $114
2021 $563 $137 $35–$551 $132
2022 $502 $137 $37–$512 $149
2023 $367 $149 $42–$545 $160
2024 $127 $156 $44–$560 $164
2025 $0 $155 $45–$549 $169

Breakdown

Who paid General payments · program years 2019–2024
  1. AbbVie, Inc. $398 19 payments
  2. Janssen Pharmaceuticals, Inc $243 17 payments
  3. Amgen Inc. $179 10 payments
  4. Astellas Pharma US Inc $144 7 payments
  5. Allergan Inc. $136 7 payments
  6. Salix Pharmaceuticals, a division of Bausch Health US, LLC $134 10 payments
  7. AstraZeneca Pharmaceuticals LP $132 9 payments
  8. Otsuka America Pharmaceutical, Inc. $128 6 payments
  9. Lilly USA, LLC $113 9 payments
  10. GlaxoSmithKline, LLC. $111 8 payments
  11. Other $749 49 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2024
  1. Food and Beverage $2,466 151 payments
Products named General payments · program years 2019–2024
  1. XARELTO $243 17 payments
  2. UBRELVY $237 10 payments
  3. XIFAXAN $134 10 payments
  4. VRAYLAR $129 7 payments
  5. REXULTI $128 6 payments
  6. EVENITY $116 7 payments
  7. Prolia $116 7 payments
  8. INVOKANA $108 8 payments
  9. FARXIGA $102 7 payments
  10. TOUJEO $92 6 payments
  11. Other $1,789 115 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 25 drugs

Part D claims

565

Median for Family Practice: 1,826

Drug cost

$31,397

Median for Family Practice: $120,094

Branded share of claims

16.3%

Median for Family Practice: 18.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Farxiga Dapagliflozin Propanediol Brand 24 $14,566
Myrbetriq Mirabegron Brand 11 $7,798
Toujeo Solostar Insulin Glargine,hum.Rec.Anlog Brand 11 $4,463
Levothyroxine Sodium Generic 55 $621
Np Thyroid Thyroid,pork Brand 14 $537
Potassium Chloride Generic 23 $528
Omeprazole Generic 31 $256
Liothyronine Sodium Generic 13 $222
Atorvastatin Calcium Generic 33 $214
Simvastatin Generic 36 $213

The 10 drugs with the highest cost, of 25 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 105,120 Part D prescribers listed as Family Practice; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 15 billing codes

Paid by Medicare

$606

Medicare's payments for the services billed

Medicare patients

14

Average age 73

Services billed

60

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Alzheimer's or dementia 0%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

151 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Family Medicine in Wyoming

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record